# SUNSHINE LAKE PHARMA CO., LTD.

# 廣東東陽光藥業股份有限公司

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 6887)**

## VOLUNTARY ANNOUNCEMENT

## ACCEPTANCE OF DRUG MARKETING AUTHORISATION APPLICATION FOR VONOPRAZAN FUMARATE AND SODIUM CHLORIDE INJECTION

This announcement is made by Sunshine Lake Pharma Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis.

The board of directors of the Company (the "**Board**") is pleased to announce that, recently, the drug marketing authorisation application for the Company's improved new drug, Vonoprazan Fumarate and Sodium Chloride Injection, has been accepted by China's National Medical Products Administration (acceptance number: CXHS2600048). The indication is for the treatment of peptic ulcer bleeding.

Vonoprazan is a novel potassium-competitive acid blocker (PCAB) primarily used to treat acid-related diseases. It works by inhibiting gastric acid secretion. The Vonoprazan Fumarate and Sodium Chloride Injection developed by the Company is an improved formulation based on the already marketed Vonoprazan Fumarate tablets and is classified as a Class 2 new drug.

The submission of the marketing application is based on a multi-centre, randomised, double-blind, active-controlled Phase II/III clinical trial evaluating the safety and efficacy of Vonoprazan Fumarate and Sodium Chloride Injection in patients with peptic ulcer bleeding CTR20242400). The primary efficacy endpoint of these trials were the non-rebleeding rate within 72 hours after the initial administration (determined by the absence of active bleeding under endoscopy). The results indicate that Vonoprazan Fumarate and Sodium Chloride Injection can effectively control the risk of rebleeding in patients with peptic ulcer bleeding, and demonstrates a favourable safety profile.

Currently, the formulations of Vonoprazan Fumarate approved in the PRC are all oral dosage forms, which are unable to meet the clinical treatment needs of patients with acute peptic ulcer bleeding. Peptic ulcer bleeding is the leading cause of upper gastrointestinal haemorrhage in the PRC, accounting for over 50% of cases, and is one of the most common clinical emergencies. Studies indicate that the annual incidence ranges from 19.4 to 57.0 per 100,000, with a rebleeding rate of 13.9% within seven days of onset and a mortality rate of 8.6%. Although acid-suppressing drugs, represented by Proton Pump Inhibitors (PPIs) formulations, are generally well tolerated and effective for most patients with peptic ulcer bleeding, there is still room for improvement. P-CABs are a new class of reversible proton pump inhibitors. Compared with standard treatment using traditional PPIs, they offer significant clinical advantages, including good acid stability (unaffected by environmental pH), efficacy from the first dose, rapid onset of action, and resolution of the problem of nocturnal acid breakthrough. Vonoprazan Fumarate and Sodium Chloride Injection is a ready-to-use large-volume parenteral solution that requires no additional preparation in a clinical setting. This not only effectively reduces the risk of contamination by pathogens and insoluble particles, but also avoids potential medication errors during preparation, thereby enhancing both the safety and convenience of drug administration. It is expected to bring a new breakthrough in the treatment options for patients with peptic ulcer bleeding.

**This announcement is made by the Company on a voluntary basis to keep investors informed of the latest business development of the Group, and contains no advertisement or intention regarding the use of any drug, surgical device, therapy or oral product.**

By order of the Board
**Sunshine Lake Pharma Co., Ltd.**
**Dr. ZHANG Yingjun**
*Chairman*

Dongguan, the PRC
8 April 2026

*As at the date of this announcement, the executive Directors are Dr. ZHANG Yingjun and Dr. LI Wenjia, the non-executive Directors are Mr. ZHANG Yushuai, Mr. TANG Xinfa, Mr. ZHU Yingwei, Mr. ZENG Xuebo, Ms. DONG Xiaowei and Ms. WANG Lei, and the independent non-executive Directors are Dr. LI Xintian, Dr. MA Dawei, Dr. YIN Hang Hubert, Dr. LIN Aimei and Dr. YE Tao.*